Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naΓ―ve in the advanced setting was 77.3 months Median OS among patients previously treated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -1.29645635264 | 11.57 | 11.72 | 10.77 | 181934 | 11.12578022 | CS |
4 | -1.55 | -11.9506553585 | 12.97 | 13.91 | 10.3537 | 295441 | 12.14545321 | CS |
12 | -4.16 | -26.7008985879 | 15.58 | 16.5431 | 10.3537 | 301407 | 12.97386398 | CS |
26 | -6.85 | -37.4931581828 | 18.27 | 19.77 | 10.3537 | 297054 | 14.7155143 | CS |
52 | -3.83 | -25.1147540984 | 15.25 | 22.188 | 10.3537 | 284756 | 15.77475859 | CS |
156 | 0.525 | 4.81872418541 | 10.895 | 22.188 | 4.81 | 142808 | 14.02707589 | CS |
260 | 0.28 | 2.51346499102 | 11.14 | 33.01 | 4.03 | 117921 | 16.00375556 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.